Aurobindo Pharma has informed that it has disclosed the receipt of the above referred cautionary e-mails to the stock exchanges on March 28, 2025. The company has submitted the disclosure again in the prescribed format as Annexure to this letter.
The above information is a part of company’s filings submitted to BSE.